Gilead's Kite Launches Phase 1 Trial of KITE-363, a CAR-T Therapy for Autoimmune Neurological Diseases
Expanding into the Autoimmune Space: A Leading Cell Therapy Company
Gilead Sciences' subsidiary, Kite, has embarked on a full-fledged expansion into the autoimmune disease area. Kite, a leading cell therapy company that has successfully launched blockbuster products such as Yescarta in the oncology field, has initiated a Phase 1 trial (NCT07304154) of KITE-363, a CAR-T cell therapy for autoimmune neurological diseases. KITE-363 is an autologous, dual-targeting CAR-T cell therapy that simultaneously targets CD19 and CD20. This clinical trial marks Gilead's strategic move to diversify its pipeline into the autoimmune disease area, which is gaining attention as a new high-growth market amidst intensifying competition in the anti-cancer cell therapy market.
Phase 1 Trial Design Targeting Refractory Neurological Diseases
The clinical trial is designed to include patients with relapsed or refractory autoimmune neurological diseases who have not responded to existing treatments. Specifically, patients with multiple sclerosis (MS), myasthenia gravis (MG), and chronic inflammatory demyelinating polyneuropathy (CIDP) will participate. The trial consists of a Phase 1a dose-escalation phase and a Phase 1b phase to verify the safety of the optimal dose, comprehensively evaluating the tolerability and pharmacokinetic characteristics of KITE-363. This represents the first step in verifying the potential of KITE-363 as a one-time treatment that can fundamentally reset the disease, moving away from conventional chronic immunosuppressive therapies.
Differentiated Mechanism of Action: Dual Targeting of CD19 and CD20
The key technological aspect of KITE-363 is that it blocks both CD19 and CD20, two antigens that appear in different developmental stages of B cells. This plays a crucial role in preventing the antigen escape phenomenon that is often induced by single-target CD19 CAR-T therapies, which are commonly adopted by competitors. By more broadly depleting both pathogenic B cells and early plasmablasts that secrete autoantibodies, it can maximize therapeutic efficacy. This multifaceted targeting mechanism is expected to act as a key mechanism for inducing long-term remission by disrupting the abnormal immune system activity that attacks the nervous system.
Leading Competitive Advantage and Manufacturing Infrastructure
The autoimmune CAR-T field is currently a battleground with fierce competition among leading companies such as Kyverna Therapeutics (KYV-101) and Cabaletta Bio (CABA-201). However, Gilead has a unique competitive advantage in that it is the only company that has successfully established large-scale commercial manufacturing and supply chain infrastructure for CAR-T therapies for cancer patients. Combined with efficacy and safety data proven in clinical trials, Gilead's accumulated manufacturing capabilities in the cell therapy field will likely enable it to rapidly secure market share in the autoimmune market.
Gilead's entry into the autoimmune neurological disease market, including multiple sclerosis (MS), a $30 billion annual market, leveraging its manufacturing and commercialization capabilities established through the development of its global blockbuster CAR-T therapy Yescarta, marks a milestone in its long-term portfolio diversification strategy. KITE-363, with its dual-targeting design targeting both CD19 and CD20, is likely to demonstrate superior B-cell depletion efficacy and antigen escape inhibition compared to competitors with single-target CD19 CAR-T pipelines, such as Kyverna Therapeutics (KYV-101, Phase 1/2) and Cabaletta Bio (CABA-201, Phase 1/2). In the short term, securing valid safety data and initial remission responses through the ongoing Phase 1 trial (NCT07304154) will be a key milestone for advancing to later-stage clinical trials and enhancing pipeline value. In the long term, it will drive the shift from conventional chronic immunosuppressive treatment paradigms to a one-step cell therapy reset approach, positioning Gilead to capture a high-value market for patients with severe, refractory neurological diseases.
Source: ClinicalTrials.gov (api_ct)